WallStSmart

Monster Beverage Corp (MNST)vsPrenetics Global Ltd (PRE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Monster Beverage Corp generates 5863% more annual revenue ($9.22B vs $154.59M). MNST leads profitability with a 23.1% profit margin vs -30.4%. MNST earns a higher WallStSmart Score of 64/100 (C+).

MNST

Buy

64

out of 100

Grade: C+

Growth: 7.3Profit: 9.0Value: 6.0Quality: 7.8
Piotroski: 4/9Altman Z: 6.29

PRE

Avoid

30

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -0.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MNSTUndervalued (+70.3%)

Margin of Safety

+70.3%

Fair Value

$145.88

Current Price

$44.63

$101.25 discount

UndervaluedFair: $145.88Overvalued

Intrinsic value data unavailable for PRE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MNST6 strengths · Avg: 8.8/10
Altman Z-ScoreHealth
6.2910/10

Safe zone — low bankruptcy risk

Market CapQuality
$85.02B9/10

Large-cap with strong market position

Return on EquityProfitability
22.7%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
23.1%9/10

Keeps 23 of every $100 in revenue as profit

Operating MarginProfitability
29.2%8/10

Strong operational efficiency at 29.2%

Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

PRE2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
210.7%10/10

Revenue surging 210.7% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Areas to Watch

MNST3 concerns · Avg: 3.3/10
PEG RatioValuation
2.224/10

Expensive relative to growth rate

Price/BookValuation
9.3x4/10

Trading at 9.3x book value

P/E RatioValuation
40.2x2/10

Premium valuation, high expectations priced in

PRE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$426.87M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-72.7%2/10

ROE of -72.7% — below average capital efficiency

Free Cash FlowQuality
$-30.91M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MNST

The strongest argument for MNST centers on Altman Z-Score, Market Cap, Return on Equity. Profitability is solid with margins at 23.1% and operating margin at 29.2%. Revenue growth of 20.2% demonstrates continued momentum.

Bull Case : PRE

The strongest argument for PRE centers on Revenue Growth, Debt/Equity. Revenue growth of 210.7% demonstrates continued momentum.

Bear Case : MNST

The primary concerns for MNST are PEG Ratio, Price/Book, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.

Bear Case : PRE

The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MNST profiles as a growth stock while PRE is a hypergrowth play — different risk/reward profiles.

MNST carries more volatility with a beta of 0.52 — expect wider price swings.

PRE is growing revenue faster at 210.7% — sustainability is the question.

MNST generates stronger free cash flow (461M), providing more financial flexibility.

Bottom Line

MNST scores higher overall (64/100 vs 30/100), backed by strong 23.1% margins and 20.2% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Monster Beverage Corp

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Monster Beverage Corporation is an American beverage company that manufactures energy drinks including Monster Energy, Relentless and Burn.

Visit Website →

Prenetics Global Ltd

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Prenetics Global Ltd (PRE) is an innovative health technology company that specializes in advanced genetic and diagnostic testing solutions, offering invaluable health insights to consumers and healthcare professionals alike. With a robust focus on research and development, Prenetics has built a strong international footprint through strategic partnerships and collaborations, enhancing its market visibility. As a frontrunner in personalized medicine, the company is strategically positioned to leverage the growing demand for accessible health data, presenting a compelling investment opportunity within the dynamic healthcare sector.

Want to dig deeper into these stocks?